Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Tumor Progression02:07

Tumor Progression

7.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Cdcp1 Overexpression Drives Prostate Cancer Progression And Can Be Targeted In Vivo.

CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.

Abdullah Alajati1,2, Mariantonietta D'Ambrosio1,2,3, Martina Troiani1,2

  • 1Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.

The Journal of Clinical Investigation
|April 7, 2020

Related Experiment Videos

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

9.1K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.6K
Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells
08:03

Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells

Published on: October 20, 2015

14.5K

View abstract on PubMed

Summary
This summary is machine-generated.

Castration-resistant prostate cancer (CRPC) progression is driven by CUB domain-containing protein 1 (CDCP1) overexpression, especially with PTEN loss. Targeting CDCP1 offers new therapeutic strategies for metastatic prostate tumors.

Keywords:
OncologyProstate cancer

Related Experiment Videos

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

9.1K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.6K
Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells
08:03

Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells

Published on: October 20, 2015

14.5K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Prostate cancer's transition to castration-resistant prostate cancer (CRPC) is poorly understood.
  • Identifying genetic alterations driving CRPC is crucial for developing new therapies.
  • CUB domain-containing protein 1 (CDCP1) is a transmembrane protein implicated in cancer progression.

Purpose of the Study:

  • To investigate the role of CDCP1 in the development of CRPC.
  • To identify mechanisms linking CDCP1 to prostate cancer metastasis.
  • To explore therapeutic strategies targeting CDCP1 in metastatic prostate cancer.

Main Methods:

  • Analysis of CDCP1 expression in CRPC patient samples.
  • Investigating the interaction between CDCP1, PTEN loss, and androgen signaling.
  • Utilizing anti-CDCP1 immunoliposomes (anti-CDCP1 ILs) in combination with enzalutamide for treatment studies.

Main Results:

  • CDCP1 is overexpressed in a subset of CRPC and cooperates with PTEN loss to promote metastasis.
  • Androgen deprivation combined with PTEN loss upregulates CDCP1, activating the SRC/MAPK pathway.
  • Anti-CDCP1 ILs loaded with chemotherapy suppressed tumor growth when combined with enzalutamide.

Conclusions:

  • CDCP1 is a significant driver of prostate cancer progression to the metastatic CRPC stage.
  • The interplay between androgens, PTEN, and CDCP1 is a key mechanism in CRPC development.
  • Targeting CDCP1, potentially with immunoliposomes and chemotherapy, presents a viable therapeutic approach for metastatic prostate cancer.